Medicaid spending on naloxone increased 13,500% in recent years, study finds

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this material? View our policies by clicking here.

More posts on opioids:49 states file $2.15 trillion opioid epidemic claim against Purdue Pharma80% of Americans cant accurately recognize opioids, study findsOpioid use condition treatment inaccessible for lots of Appalachian patients, research study finds.

Medicaid spending on opioid overdose-reversal drug naloxone shot up from $110,000 in 2010 to close to $15 million in 2018, according to a research study released Aug. 26 by Washington, D.C., think tank the Urban Institute.

Katie Adams –
Wednesday, August 26th, 2020
Print|Email.

The research study also discovered a 7,050 percent increase in the variety of Medicaid naloxone prescriptions, with the total escalating from 3,300 in 2010 to more than 236,000 in 2018..

Much of the costs went towards Narcan, the naloxone nasal spray that can treat opioid overdose in emergency situation scenarios. In 2010, practically every naloxone prescription was for a generic variation of the drug. Generic prescriptions made up only 11 percent of total naloxone prescriptions in 2018, with the rest being released for Narcan.